Continuous high speed growth over the past 20 years since its establishment as a subsidiary in 1996
Possession of full value chain including R&D, production, marketing and sales
Selected as a role model for Korean companies entering China

Approximately 500 R&D employees
Investing about 20% of sales into R&D
8 billion dollars worth licensing agreements in 2015.

Numerous collaborations experience with many domestic and overseas partners
Establishment of close relations with domestic and overseas industries, universities and institutes
Implementation of diverse cooperation models

Leading R&D of incrementally modified drugs in Korea
First in the world to apply RFID to all products
Selected as ‘Future Representative Company’ that will lead the Korean economy in 10 years